Table 1.

Combinatorial synergy between Ly49D receptor, IL-12 and IL-18



IL-18 dose
Control IgG pretreatment
Anti-Ly49D (4E5) pretreatment
IL-12 dose, ng/mL
0 ng/mL
10 ng/mL
1 ng/mL
0.1 ng/mL
0 ng/mL
10 ng/mL
1 ng/mL
0.1 ng/mL
0   2   16   15   6.4   22   1 244   127.8   56.9  
10   2   19 900   21 300   20 300   1544   31 400   34 300   34 500  
1   8   18 400   23 100   2 364   104   32 900   30 100   29 000* 
0.1   12   17 400   18 900   0   223   27 300   27 700   25 200* 
0   —   —   —   —   20  1 228  113  51 
10   —   —   —   —   1542  11 500  13 000  14 200* 
1   —   —   —   —   96  14 500  7 000  26 636* 
0.1
 

 

 

 

 
12
 
9 900
 
8 800
 
25 200*
 


IL-18 dose
Control IgG pretreatment
Anti-Ly49D (4E5) pretreatment
IL-12 dose, ng/mL
0 ng/mL
10 ng/mL
1 ng/mL
0.1 ng/mL
0 ng/mL
10 ng/mL
1 ng/mL
0.1 ng/mL
0   2   16   15   6.4   22   1 244   127.8   56.9  
10   2   19 900   21 300   20 300   1544   31 400   34 300   34 500  
1   8   18 400   23 100   2 364   104   32 900   30 100   29 000* 
0.1   12   17 400   18 900   0   223   27 300   27 700   25 200* 
0   —   —   —   —   20  1 228  113  51 
10   —   —   —   —   1542  11 500  13 000  14 200* 
1   —   —   —   —   96  14 500  7 000  26 636* 
0.1
 

 

 

 

 
12
 
9 900
 
8 800
 
25 200*
 

Liver lymphocytes were obtained from untreated B6 mice and from mice pretreated with IL-12 or IL-18 at specified doses at 37°C for 30 minutes. Cells were washed, chilled, and coated with anti-NKRs for 20 minutes and then washed and cultured for 4 hours. Values represent pg/mL of IFNγ.

— indicates not applicable.

*

Dose combinations in which strong synergy was observed

Difference from control IgG

Close Modal

or Create an Account

Close Modal
Close Modal